Skip to content

Russell Bowler, M.D., Ph.D. obtained a B.S. in mathematical and computational sciences from Stanford University, a M.D. from the University of California at San Francisco (UCSF), and a Ph.D. in Cell and Developmental Biology from the University of Colorado (CU). He completed his internal medicine residency at UCSF and a pulmonary and critical care fellowship from CU.

The mission of our lab is to understand the mechanisms of how inhaled smoke (cigarette or cannabis smoke and vaping) leads to the development of chronic obstructive pulmonary disease (COPD), the third leading cause of death in the United States. We have generated genetic, genomic, metabolic profiles on 10,000 subjects in the NIH sponsored COPDGene and SPIROMICS cohort and use these Omics data to identify novel diagnostic and therapeutic targets. Our laboratory also uses mouse models to study the mechanisms of smoke induced lung disease. We also use wearable sensors and artificial intelligence/machine learning to develop algorithms for at-home detection of COPD exacerbations.

Lab Resources and Services

The Bowler Laboratory offers high-throughput genomic, proteomic, and metabolic profiling. Additionally, oxidative stress, antioxidant measurements,  and translational models in COPD (cigarette smoke extract, whole smoke).

Current Projects

  • GWAS, Genome, Metabolome and proteome profiles of emphysema and airway disease
  • Cigarette smoke induces endogenous oxidant injury
  • Vaping effects on young adults
  • Using wearable sensors and AI/ML to detect COPD exacerbations while at home
  • New biologic therapy for COPD

Currently Enrolling Research Projects


  • Principal Investigator
    Russell P. Bowler, MD, PhD
  • Lab Researchers
    • Elena Engel, BS, CRC II
    • Ari McCallum, BS, CRC II
    • Claire Guo, MS, Analyst
    • Sophia Addi, MS, Laboratory Technician
    • Andrew Hill, MS, Analyst
  • Postdoctoral fellow
    • Lisa Ruvuna, MD



Serban KA, Pratte KA, Strange C, Sandhaus RA, Turner AM, Beiko T, Spittle DA, Maier L, Hamzeh N, Silverman EK, Hobbs BD, Hersh CP, DeMeo DL, Cho MH, Bowler RPUnique and shared systemic biomarkers for emphysema in Alpha-1 Antitrypsin deficiency and chronic obstructive pulmonary disease. EBioMedicine. 2022 Oct;84:104262. doi: 10.1016/j.ebiom.2022.104262. Epub 2022 Sep 22. PubMed PMID: 36155958; PubMed Central PMCID: PMC9507992.

More Publications